Mark Shepherd, Respiratory Physics Lab and Workshop Manager at Team Consulting, will attempt to set a world record by climbing to the top of the Empire State Building in New York City while carrying 125 kg on his back. The attempt will take place on May 26, 2012 and will benefit the Myositis Support Group, a UK charity. To date, Shepherd has raised £370,000 through … [Read more...] about OINDP specialist Mark Shepherd to attempt world record
News
Jesse Zhu wins Distinguished University Professorship
The University of Western Ontario has named particle technology researcher Jesse Zhu a 2012 Distinguished University Professorship winner. Zhu, a professor and Canada Research Chair in Powder Technology Applications in the Department of Chemical and Biochemical Engineering at Western, has published a number of papers related to dry powder inhalation. Zhu has been … [Read more...] about Jesse Zhu wins Distinguished University Professorship
QVA 149 Phase 3 studies meet primary endpoints
Three Phase 3 studies of Novartis's QVA149 indacaterol /glycopyrronium bromide dry powder inhaler for the treatment of COPD have met their primary endpoints according to the company. The SHINE study demonstrated superiority in trough FEV1 for QVA 149 compared to indacaterol alone, glycopyrronium alone, tiotropium, and placebo in more than 2,000 patients with moderate … [Read more...] about QVA 149 Phase 3 studies meet primary endpoints
European rights to aclidinium bromide to Menarini, review period extended by the FDA
Almirall has licensed European rights to aclidinium bromide, both as a monotherapy and in combination with formoterol to Italian pharmaceutical company Menarini. The agreement covers most of the EU except for the UK, the Netherlands and the Nordic countries, plus several additional countries, including Russia and Turkey. Almirall CEO Eduardo Sanchiz explained, … [Read more...] about European rights to aclidinium bromide to Menarini, review period extended by the FDA
Bausch + Lomb to acquire ISTA Pharmaceuticals
After spurning repeated offers from Valeant, ISTA Pharmaceuticals has agreed to be acquired by Bausch + Lomb for $9.10 per share in cash, a total of about $500 million. Valeant had offered $7.50 per share. In addition to its eyecare products, ISTA has been developing two bepotastine nasal sprays for allergic rhinitis, one a single therapy product and the other a … [Read more...] about Bausch + Lomb to acquire ISTA Pharmaceuticals
MAP gets complete response letter for Levadex inhaled dihydroergotamine
The FDA has issued a complete response letter to MAP Pharmaceuticals' NDA for Levadex dihydroergotamine inhalation aerosol for the treatment of migraine headaches. According to MAP, "the FDA requested that the Company address issues relating to chemistry, manufacturing and controls (CMC) and observations from a recent facility inspection of a third party manufacturer. … [Read more...] about MAP gets complete response letter for Levadex inhaled dihydroergotamine
Engineering firm discloses DPI filling technology
A Massachusetts engineering firm called Enginasion has disclosed details of proprietary DPI-filling technology it says that it developed for a pharmaceutical client that needed accurate dispensing of a highly cohesive inhaled dry powder formulation into cartridges. Enginasion Founder and CEO David Bonneau is the co-author of several patents assigned to MannKind … [Read more...] about Engineering firm discloses DPI filling technology
FDA approves QNASL HFA nasal aerosol
According to Teva, the FDA has approved its QNASL HFA beclomethasone dipropionate nasal aerosol for the treatment of seasonal and perennial allergic rhinitis in adults and children 12 years of age and older, and the company plans to launch the product by the end of April 2012. QNASL is delivered by a pressurized nasal delivery device that includes a dose counter. Teva … [Read more...] about FDA approves QNASL HFA nasal aerosol
Almirall publishes full results from aclidinium bromide study
Almirall has published full results from the ATTAIN (Aclidinium To Treat Airway obstruction In COPD patieNts) study in The European Respiratory Journal (ERJ). ATTAIN was a six-month double-blind placebo-controlled study that compared two doses of inhaled aclidinium (200μg and 400μg twice daily) to placebo in patients with COPD. According to the company the 400 µg dose … [Read more...] about Almirall publishes full results from aclidinium bromide study
GSK still going ahead with Relovair marketing applications
According to GlaxoSmithKline and Theravance, the two companies have now completed all studies for the Relovair fluticasone furoate (FF)/vilanterol (VI) DPI for both COPD and asthma, and they plan to move forward now with regulatory submissions. GSK had previously announced that it would submit marketing applications for Relovair despite the fact that the FF/VI … [Read more...] about GSK still going ahead with Relovair marketing applications